These results imply a transition in the regulation of SRD5A3 expression with prostate cancer pathogenesis and progression—a loss of positive regulation and gain of negative regulation—which is consistent with the report that a lower testosterone level was found among prostate cancer patients with higher Gleason scores than that in those with lower Gleason scores [46]. The gene discussed is SRD5A3; the disease is prostate carcinoma.